(0.09%) 5 521.75 points
(0.14%) 39 899 points
(0.17%) 19 785 points
(-0.07%) $81.57
(0.68%) $2.83
(-0.26%) $2 338.20
(0.10%) $29.56
(0.48%) $1 006.60
(0.06%) $0.932
(-0.02%) $10.53
(0.00%) $0.788
(-0.85%) $87.25
-0.44% $ 27.33
Live Chart Being Loaded With Signals
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States...
Stats | |
---|---|
Dzisiejszy wolumen | 437 531 |
Średni wolumen | 594 824 |
Kapitalizacja rynkowa | 736.05M |
EPS | $-1.000 ( Q1 | 2024-05-08 ) |
Następna data zysków | ( $-1.500 ) 2024-08-05 |
Last Dividend | $0.0596 ( 2013-01-08 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-6.78 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0440 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-19 | Slaoui Moncef | Buy | 15 000 | Stock option (right to buy) |
2024-06-19 | Slaoui Moncef | Buy | 14 794 | Stock option (right to buy) |
2024-06-19 | Slaoui Moncef | Buy | 0 | |
2024-06-14 | Marantz Jing L. | Buy | 15 000 | Stock option (right to buy) |
2024-06-14 | Marantz Jing L. | Buy | 3 131 | Common Stock |
INSIDER POWER |
---|
62.09 |
Last 97 transactions |
Buy: 2 172 015 | Sell: 251 872 |
Wolumen Korelacja
Arcturus Therapeutics Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
OZEM | 1 |
WSC | 0.882 |
AKYA | 0.87 |
REE | 0.869 |
ASUR | 0.867 |
DOMO | 0.866 |
CTSH | 0.864 |
CRBU | 0.863 |
BMEA | 0.861 |
ATHA | 0.86 |
10 Najbardziej negatywne korelacje | |
---|---|
MGX | -0.862 |
OMH | -0.859 |
AMRK | -0.856 |
HYMC | -0.844 |
NA | -0.841 |
ALCE | -0.84 |
NVNI | -0.84 |
ICUCW | -0.839 |
SGHT | -0.836 |
ABAT | -0.835 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Arcturus Therapeutics Korelacja - Waluta/Towar
Arcturus Therapeutics Finanse
Annual | 2023 |
Przychody: | $157.75M |
Zysk brutto: | $154.79M (98.13 %) |
EPS: | $-1.120 |
FY | 2023 |
Przychody: | $157.75M |
Zysk brutto: | $154.79M (98.13 %) |
EPS: | $-1.120 |
FY | 2022 |
Przychody: | $205.76M |
Zysk brutto: | $62.70M (30.48 %) |
EPS: | $0.350 |
FY | 2021 |
Przychody: | $12.36M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-7.74 |
Financial Reports:
No articles found.
Arcturus Therapeutics Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0200 | 2012-03-06 |
Last Dividend | $0.0596 | 2013-01-08 |
Next Dividend | $0 | N/A |
Payout Date | 2013-01-15 | |
Next Payout Date | N/A | |
# dividends | 12 | -- |
Total Paid Out | $0.679 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.71 | -- |
Div. Sustainability Score | 2.87 | |
Div.Growth Potential Score | 1.048 | |
Div. Directional Score | 1.959 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0 | 0.00% |
2013 | $0.119 | 0.23% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
08 Jan 2013 | $0.0596 | 27 Dec 2012 | 08 Jan 2013 | 15 Jan 2013 |
04 Jan 2013 | $0.0596 | 27 Dec 2012 | 08 Jan 2013 | 15 Jan 2013 |
05 Dec 2012 | $0.0600 | 28 Nov 2012 | 30 Nov -0001 | 15 Dec 2012 |
06 Nov 2012 | $0.0600 | 26 Oct 2012 | 30 Nov -0001 | 15 Nov 2012 |
03 Oct 2012 | $0.0600 | 27 Sep 2012 | 30 Nov -0001 | 15 Oct 2012 |
05 Sep 2012 | $0.0600 | 01 Aug 2012 | 30 Nov -0001 | 15 Sep 2012 |
06 Aug 2012 | $0.0600 | 26 Jul 2012 | 30 Nov -0001 | 15 Aug 2012 |
03 Jul 2012 | $0.0600 | 27 Jun 2012 | 30 Nov -0001 | 15 Jul 2012 |
06 Jun 2012 | $0.0600 | 29 May 2012 | 30 Nov -0001 | 15 Jun 2012 |
04 May 2012 | $0.0600 | 27 Apr 2012 | 30 Nov -0001 | 15 May 2012 |
03 Apr 2012 | $0.0600 | 14 Mar 2012 | 30 Nov -0001 | 15 Apr 2012 |
06 Mar 2012 | $0.0200 | 02 Mar 2012 | 30 Nov -0001 | 15 Mar 2012 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.916 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.249 | 1.200 | -8.29 | -9.95 | [0 - 0.3] |
returnOnEquityTTM | -0.376 | 1.500 | -5.29 | -7.94 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.26 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.73 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.50 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0762 | -1.500 | 8.73 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -4 842.17 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.458 | 2.00 | 9.85 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.368 | 2.00 | 9.82 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.121 | -1.500 | 9.52 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.570 | 1.000 | 3.83 | 3.83 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1.022 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.385 | 1.000 | 8.97 | 8.97 | [0.2 - 2] |
assetTurnoverTTM | 0.272 | 0.800 | -1.523 | -1.218 | [0.5 - 2] |
Total Score | 2.87 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -7.05 | 1.000 | -0.813 | 0 | [1 - 100] |
returnOnEquityTTM | -0.376 | 2.50 | -3.40 | -7.94 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.368 | 2.00 | 9.88 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.458 | 2.00 | 9.85 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.541 | 1.500 | -6.94 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.108 | 1.000 | 9.80 | 0 | [0.1 - 0.5] |
Total Score | 1.048 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej